Cyclophosphamide
Brand Names: Frindovyx, Cytoxan
Methodology & AI Transparency ⓘ
Cyclophosphamide Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cyclophosphamide is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma.
- 2 Real-world patient consensus: 85% patient "Worth It" rating across 13 anonymous logs for Cyclophosphamide (RxNorm 2386859).
- 3 Typical cash cost range: Dispensing cost comparison spans $27.88 mail/discount cash up to $68.31 uninsured retail (federal NADAC $1.1747).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Cyclophosphamide): nausea (11%), diarrhea (8.3%), vomiting (4.6%).
Ask our AI Specialists anything about Cyclophosphamide
Cyclophosphamide Mechanism, CYP450 Pathways & DailyMed Monograph
Cyclophosphamide is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma.
12.1 Mechanism of Action The mechanism of action has not been fully characterized. However, cross-linking of tumor cell DNA may be involved. The active alkylating metabolites of cyclophosphamide interfere with the growth of susceptible rapidly proliferating malignant cells. 12.2 Pharmacodynamics Cyclophosphamide exposure-response relationships and the time course of pharmacodynamic response have not been fully characterized. 12.3 Pharmacokinetics Cyclophosphamide is a prodrug. Cyclophosphamide pharmacokinetics are linear over the approved recommended dose range.
Clinical clearance of Cyclophosphamide (Alkylating Drug) relies on hepatic enzymatic processing and renal clearance proportional to creatinine clearance (cyclophosphamide) with a Biphasic clearance with 5–12 hr terminal t½ under Cyclophosphamide maintenance half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Cyclophosphamide (1 g/50mL Injection, Powder, for Solution) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after cyclophosphamide administration.
FDA clinical labeling for Cyclophosphamide restricts administration in anaphylactic reactions including death have been reported with cyclophosphamide.; cross-sensitivity with other alkylating agents can occur. across 1 g/50mL Injection, Powder, for Solution, 1 g/2mL Injection, 500 mg/25mL Injection, Powder, Lyophilized, for Solution, 1 g/50mL Injection, Powder, Lyophilized, for Solution, 1 g/5mL Injection, with self-reported patient tracking dominated by nausea (11% of reports), diarrhea (8.3% of reports), headache (7.2% of reports).
Avoid overlapping alkylating drug prescriptions alongside Cyclophosphamide to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Cyclophosphamide dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Anaphylactic reactions including death have been reported with cyclophosphamide.
- Cross-sensitivity with other alkylating agents can occur.
Logged Side-Effect Incidence (13 Reports)
Cyclophosphamide Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cyclophosphamide)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Subgroup analysis of Japanese patients in a phase III randomized, controlled Atezolizumab added to neoadjuvant chemotherapy numerically improved pathological complete response versus placebo in this small exploratory analysis of Japanese patients with early stage triple-negative breast cancer, a trend... Japanese journal of clinical oncology • 2022-10-06 • Phase III Randomized Trial | N = 36 | 88/100 | PMID 35750038 ↗ |
| Can This Approach Help? Inside the Latest Research on Central nervous system symptom burden and clinical implications for antiemetic CNS symptom burden was associated with suboptimal CINV control, while 5 mg of olanzapine maintained superior antiemetic efficacy across CNS symptom strata. The oncologist • 2026-09-09 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42714265 ↗ |
| Can This Approach Help? Inside the Latest Research on Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney Similar effects of belimumab on biomarker outcomes were observed within the induction groups. Kidney international • 2026-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42055319 ↗ |
| Can This Approach Help? Inside the Latest Research on Influence of different photobiomodulation protocols on the prevention of Protocols R or IR proved to be inferior to the R + IR laser photobiomodulation protocol. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer • 2025-07-14 • Phase III Randomized Trial | N = 60 | 88/100 | PMID 40658227 ↗ |
| Can This Approach Help? Inside the Latest Research on Six-year follow-up of participants in two clinical trials of rituximab or After six years, 44.1% of the cyclophosphamide group scored an SF-36 PF of at least 70, and 17.6% of at least 90, suggesting that cyclophosphamide in a subgroup may modulate the disease course in a beneficial way. PloS one • 2024-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39042627 ↗ |
Cyclophosphamide Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.1747/unit (~$35.24/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $27.88 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $68.31 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 13 Anonymous DotMD Community Micro-Logs | $32.06 / mo | View logs ↓ |
Cyclophosphamide Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Cyclophosphamide RxNorm Concept ID | 2386859 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.1747 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $68.31 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $27.88 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 85.00% Worth It (13 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Cyclophosphamide Patient Community, Cohort Filters & Dosage Logs
Deterministic Cyclophosphamide reference combining NIH RxNorm (2386859), Medicaid NADAC ($1.1747/unit), and anonymous cohort outcomes (85% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Cyclophosphamide community threads and patient logs by age, biological sex, dosage, and treatment duration.